FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * PIEN HOWARD H   2. Issuer Name and Ticker or Trading Symbol MEDAREX INC [MEDX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Pres., CEO & Chair. of the Brd (Last) (First) (Middle) C/O MEDAREX, INC., 707 STATE ROAD 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2009 (Street) PRINCETON, NJ 08540 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$ 14.36	09/01/2009		D			500,000	(1)	06/28/2017	Common Stock	500,000	$ 16	0	D
Stock Option (Right to Buy)	$ 9.07	09/01/2009		D			270,000	(2)	03/02/2018	Common Stock	270,000	$ 16	0	D
Stock Option (Right to Buy)	$ 3.72	09/01/2009		D			270,000	(3)	03/04/2019	Common Stock	270,000	$ 16	0	D
Restricted Stock Units	(4)	09/01/2009		D			90,000	(5)	(7)	Common Stock	90,000	$ 16	0	D
Restricted Stock Units	(4)	09/01/2009		D			90,000	(5)	(8)	Common Stock	900,000	$ 16	0	D
Restricted Stock Units	(4)	09/01/2009		D			192,360	(6)	(9)	Common Stock	192,360	$ 16	0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
PIEN HOWARD H C/O MEDAREX, INC. 707 STATE ROAD PRINCETON, NJ 08540	X		Pres., CEO & Chair. of the Brd

Signatures

Beth A. Behrend, Attorney-in-Fact		09/03/2009
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option was canceled in the merger in exchange for a cash payment of $822,500.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
(2)	This option was canceled in the merger in exchange for a cash payment of $1,872,450.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
(3)	This option was canceled in the merger in exchange for a cash payment of $3,315,600.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
(4)	Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
(5)	This restricted stock unit was canceled in the merger in exchange for a cash payment of $1,440,000.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
(6)	This restricted stock unit was canceled in the merger in exchange for a cash payment of $3,077,760.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
(7)	Receipt of the restricted stock units was deferred until March 3, 2013.
(8)	Receipt of the restricted stock units was deferred until March 5, 2013.
(9)	Receipt of the restricted stock units was deferred until March 13, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.